Stay updated with breaking news from 53220k50. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $1.13 per share for the quarter. Ligand Pharmaceuticals has set its FY 2024 guidance at 4.250-4.750 EPS and its FY24 guidance at $4.25 to $4.75 EPS.Investors […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.13 per share for the quarter. Ligand Pharmaceuticals has set its FY 2024 guidance at 4.250-4.750 EPS and its FY24 guidance at $4.25 […]
Cetera Trust Company N.A purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,205 shares of the biotechnology company’s stock, valued at approximately $157,000. Several other institutional investors and hedge funds have also […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $74.42, but opened at $85.18. Ligand Pharmaceuticals shares last traded at $89.46, with a volume of 162,105 shares changing hands. Wall Street Analyst Weigh In Separately, Benchmark restated a “buy” rating […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) – Investment analysts at Zacks Research lowered their FY2023 earnings per share estimates for Ligand Pharmaceuticals in a note issued to investors on Tuesday, November 28th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $4.13 for the year, down […]